ClinicalTrials.gg
CompletedNCT07240116Updated Apr 13, 2026

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

A Phase 1 interventional study of Miricorilant Treatment A and Miricorilant Treatment B in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This single-center, randomized, open-label study will assess the relative bioavailability of 2 miricorilant (CORT118335) tablet formulations.

Read the detailed description

This study will evaluate relative bioavailability of Kinetisol and spray dried dispersion (SDD) miricorilant (CORT118335) tablets. This study will consist of 6 possible treatment sequences across 3 periods for healthy, fed participants. A fourth period may be added to assess the impact of fasted conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand written
  • Willing and able to comply with study requirements
  • Willing to comply with protocol-specified requirements
  • Healthy male or non-pregnant, non-lactating female of non- per Investigator assessment.
  • (BMI) of 18.0 to 30.0 kg/m\^2 at screening
  • Weight of at least 50 kg at screening

Exclusion criteria

Exclusion Criteria:

  • Serious adverse reaction or to any drug or formulation
  • History of allergy requiring treatment
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder
  • Any form of cancer within the 5 years before the first does of this study
  • History and/or symptoms of adrenal insufficiency
  • History of clinically significant GI disease
  • Condition or history of a condition that could be aggravated by antagonism or glucocorticoid activation
  • History of additional risk factors for torsades de pointes
  • Poor venous access that limits phlebotomy
  • Clinically significant abnormal clinical chemistry, hematology or urinalysis
  • History or evidence of hypokalemia
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) 1 and 2 antibody results
  • Evidence of renal impairment at screening
  • Positive serum or highly sensitive urine pregnancy test at screening or first admission
  • Clinically significant abnormalities or vital sign abnormalities at screening or baseline
  • Received any medicinal products (IMP) in a clinical research study within 5 half-lives or within 30 days prior to first dose
  • Donation of blood within 2 months or donation of plasma within 1 week prior to first dose of study medication
  • Are taking, or have taken, any prescribed or over-the-counter drug or vitamins/herbal remedies in the 14 days before first IMP administration
  • Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months before first IMP administration or 3 months for inhaled products
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption as defined in the study protocol
  • A confirmed positive alcohol urine test at screening or first admission
  • Current smokers and those who have smoked within the last 12 months
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • A confirmed positive urine cotinine test at screening or first admission
  • Positive drug screen test result at screening or first admission
  • Male subjects with pregnant or lactating partners
  • Study site or Sponsor employee or immediate family members one
  • Failure to satisfy the Investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Miricorilant Treatment Sequence A, B, C

    Participants will receive a single dose of study drug in a fed state on Day 1 of each of 3 treatment periods. In Period 1, treatment A; in Period 2, treatment B; in Period 3, treatment C. A washout period of at least 7 days will follow each dose of the study drug.

    Drug: Miricorilant Treatment A · Drug: Miricorilant Treatment B · Drug: Miricorilant Treatment C

  • Experimental
    Miricorilant Treatment Sequence B, C, A

    Participants will receive a single dose of study drug in a fed state on Day 1 of each of 3 treatment periods. In Period 1, treatment B, in Period 2, treatment C; in Period 3, treatment A. A washout period of at least 7 days will follow each dose of the study drug.

    Drug: Miricorilant Treatment A · Drug: Miricorilant Treatment B · Drug: Miricorilant Treatment C

  • Experimental
    Miricorilant Treatment Sequence C, A, B

    Participants will receive a single dose of study drug in a fed state on Day 1 of each of 3 treatment periods. In Period 1, treatment C; in Period 2, treatment A; in Period 3, treatment B. A washout period of at least 7 days will follow each dose of the study drug.

    Drug: Miricorilant Treatment A · Drug: Miricorilant Treatment B · Drug: Miricorilant Treatment C

  • Experimental
    Miricorilant Treatment Sequence B, A, C

    Participants will receive a single dose of study drug in a fed state on Day 1 of each of 3 treatment periods. In Period 1, treatment B; in Period 2, treatment A; in Period 3, treatment C. A washout period of at least 7 days will follow each dose of the study drug.

    Drug: Miricorilant Treatment A · Drug: Miricorilant Treatment B · Drug: Miricorilant Treatment C

  • Experimental
    Miricorilant Treatment Sequence A, C, B

    Participants will receive a single dose of study drug in a fed state on Day 1 of each of 3 treatment periods. In Period 1, treatment A; in Period 2, treatment C; in Period 3, treatment B. A washout period of at least 7 days will follow each dose of the study drug.

    Drug: Miricorilant Treatment A · Drug: Miricorilant Treatment B · Drug: Miricorilant Treatment C

  • Experimental
    Miricorilant Treatment Sequence C, B, A

    Participants will receive a single dose of study drug in a fed state on Day 1 of each of 3 treatment periods. In Period 1, treatment C; in Period 2, treatment B; in Period 3, treatment A. A washout period of at least 7 days will follow each dose of the study drug.

    Drug: Miricorilant Treatment A · Drug: Miricorilant Treatment B · Drug: Miricorilant Treatment C

  • Experimental
    Optional Miricorilant Treatment D

    After completion of Period 3, analysis of pharmacokinetic and safety data will be used to decide if Period 4 will be conducted. In Period 4, selected participants will receive a single dose of treatment D in a fasted state on Day 1.

    Drug: Miricorilant Treatment D

Interventions

  • Miricorilant 100 mg (1 x 100 mg) Kinetisol immediate release (IR) tablet for oral administration

    Also known as: CORT118335

  • Miricorilant 100 mg (2 x 50 mg) Kinetisol IR tablet for oral administration

    Also known as: CORT118335

  • Miricorilant 100 mg (2 x 50 mg) SDD IR tablet for oral administration

    Also known as: CORT118335

  • Miricorilant 100 mg (1 x 100 mg or 2 x 50 mg) Kinetisol IR tablet for oral administration. The tablet strength administered will be decided after Period 3 is complete.

    Also known as: CORT118335

06

What researchers measure

Primary outcomes

  1. Time of Maximum Observed Concentration (Tmax) of Miricorilant

    Time frame: Predose and at serial timepoints up to 72 hours postdose

  2. Maximum Observed Concentration (Cmax) of Miricorilant

    Time frame: Predose and at serial timepoints up to 72 hours postdose

  3. Concentration at 24 Hours Postdose (C24) of Miricorilant

    Time frame: Predose and at serial timepoints up to 24 hours postdose

  4. Area Under the Curve from Time 0 to the Time of Last Measurable Concentration (AUC[0-last]) of Miricorilant

    Time frame: Predose and at serial timepoints up to 72 hours postdose

  5. Area Under the Curve from Time 0 Extrapolated to Infinity (AUC[0-inf]) of Miricorilant

    Time frame: Predose and at serial timepoints up to 72 hours postdose

  6. Terminal Elimination Half-Life (T1/2) of Miricorilant

    Time frame: Predose and at serial timepoints up to 72 hours postdose

  7. Relative Bioavailability (Frel) for Miricorilant Based on Cmax

    Time frame: Predose and at serial timepoints up to 72 hours postdose

  8. Frel for Miricorilant based on AUC(0-last)

    Time frame: Predose and at serial timepoints up to 72 hours postdose

  9. Frel for Miricorilant Based on AUC(0-inf)

    Time frame: Predose and at serial timepoints up to 72 hours postdose

Secondary outcomes

  1. Number of Participants with Abnormal, Clinically Significant Clinical Laboratory Findings

    Clinical laboratory findings include hematology, clinical chemistry, urinalysis.

    Time frame: Day -1 and 72 hours postdose in periods 3 and 4

  2. Number of Participants with Abnormal, Clinically Significant 12-Lead Electrocardiogram (ECG) Findings

    Time frame: Day -1, predose, and at 4 and 72 hours postdose in every study period

  3. Number of Participants with Abnormal, Clinically Significant Vital Sign Findings

    Time frame: Day -1, predose, and at serial time points up to 72 hours postdose in every study period

  4. Number of Participants with Abnormal, Clinically Significant Physical Exam Findings

    Time frame: 72 hours postdose in periods 3 and 4

  5. Number of Participants with 1 or More Adverse Events

    Time frame: Screening up to 30 days postdose

07

Study locations

1 site
  • Site 01
    Miami, Florida 33126, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2025 to primary completion in Mar 2026, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 20, 2025
StartActual
Sep 11, 2025
Primary completionActual
Mar 3, 2026
CompletionActual
Mar 3, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07240116
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Sep 11, 2025
Primary completion
Mar 3, 2026
Completion
Mar 3, 2026
Last update
Apr 13, 2026

Study contacts

Joseph Custodio, PhD
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT118335

Start the discussion